Search

Your search keyword '"Figueiredo, David Livingstone Alves"' showing total 3 results
Start Over Author "Figueiredo, David Livingstone Alves" Topic biological tumor markers
3 results on '"Figueiredo, David Livingstone Alves"'

1. Expression of cancer/testis antigens MAGE-A, MAGE-C1, GAGE and CTAG1B in benign and malignant thyroid diseases

Author

Melo, Daniel Hardy, Mamede, Rui Celso Martins, Neder, Luciano, Silva, Wilson Araújo, Barros-Filho, Mateus Camargo, Kowalski, Luiz Paulo, Pinto, Clóvis Antonio Lopes, Zago, Marco Antônio, Figueiredo, David Livingstone Alves, and Jungbluth, Achim A.

Subjects
endocrine system, biological tumor markers, thyroid neoplasms, thyroid nodule, immunohistochemistry, Articles
Abstract

Despite considerable advances in the understanding of thyroid gland biology, correctly diagnosing thyroid nodules and treating high-grade thyroid carcinoma remains challenging. Cancer/testis (CT) antigens have emerged as potential diagnostic tools as well as targets of potential cancer vaccinations. In the present study, a total of 117 patients who underwent surgical therapy for thyroid disease were available for analysis. The expression levels of melanoma-associated antigen (MAGE) A, MAGE-C1/CT7, cancer/testis antigen 1B (CTAG1B) and G antigen (GAGE) were analyzed by immunohistochemistry. None of the CT antigens were expressed in the normal thyroid or goiter. In papillary and follicular carcinoma, MAGE-A was present in 8.1% of cases, GAGE in 10.8% and CT/7MAGE-C1 and CTAG1B in 2.7% each. In medullary carcinoma, CT antigen expression was as follows: MAGE-A in 42.9% of patients; MAGE-C1/CT7 in 46.5%; GAGE in 92.9%; and CTAG1B in 3.6%. A statistically significant association was observed between the expression of G MAGE-C1/CT7 and patient gender as well as patient clinical stage (P=0.029 and 0.031, respectively). In poorly differentiated and anaplastic carcinoma cases, CT antigen expression was as follows: MAGE-A in 61.8% of cases; MAGE-C1 in 57.1%; GAGE in 66.7%; and CTAG1B in 14.4%. There was a statistically significant association between expression of GAGE and gender (P=0.043). However, there was no association between CT antigen expression and patient survival in any of the tumor entities analyzed. The current study identified a distinct expression pattern of CT antigens in malignant thyroid tumors indicating that CT antigens have the potential to outperform existing thyroid cancer biomarkers. The prevalence of CT antigens in high-grade carcinomas suggests that they serve an important biological role within malignant tumors.

Published
2017

2. Expression of cancer-testis antigens MAGE-A4 and MAGE-C1 in oral squamous cell carcinoma.

Author

Montoro, José Raphael de Moura Campos, Mamede, Rui Celso Martins, Neder Serafini, Luciano, Saggioro, Fabiano Pinto, Figueiredo, David Livingstone Alves, Silva, Wilson Araújo da, Jungbluth, Achim A., Spagnoli, Giulio Cesare, and Zago, Marco Antônio

Subjects
ANTIGENS, SQUAMOUS cell carcinoma, IMMUNOHISTOCHEMISTRY, CANCER vaccines, TREATMENT of oral cancer, TUMOR markers
Abstract

Background Tumor markers are genes or their products expressed exclusively or preferentially in tumor cells and cancer-testis antigens (CTAs) form a group of genes with a typical expression pattern expressed in a variety of malignant neoplasms. CTAs are considered potential targets for cancer vaccines. It is possible that the CTA MAGE-A4 (melanoma antigen) and MAGE-C1 are expressed in carcinoma of the oral cavity and are related with survival. Methods This study involved immunohistochemical analysis of 23 patients with oral squamous cell carcinoma (SCC) and was carried out using antibodies for MAGE-A4 and MAGE-C1. Fisher's exact test and log-rank test were used to evaluate the results. Results The expression of the MAGE-A4 and MAGE-C1 were 56.5% and 47.8% without statistical difference in studied variables and survival. Conclusion The expression of at least 1 CTA was present in 78.3% of the patients, however, without correlation with clinicopathologic variables and survival. © 2011 Wiley Periodicals, Inc. Head Neck, 2012 [ABSTRACT FROM AUTHOR]

Published
2012
Full Text
View/download PDF

3. Expression of mage-A4 and mage-C1 tumor-associated antigen in benign and malignant thyroid diseases.

Author

Melo, Daniel Hardy, Mamede, Rui Celso Martins, Neder, Luciano, Saggioro, Fabiano Pinto, Figueiredo, David Livingstone Alves, Araújo da Silva, Wilson, Jungbluth, Achim A., and Zago, Marco Antônio

Subjects
THYROID cancer, THYROID diseases, GOITER, IMMUNOHISTOCHEMISTRY, ADENOMATOID tumors, PAPILLARY carcinoma, CANCER patients
Abstract

Background A subset of thyroid tumors characterized by a follicular growth pattern can represent a serious diagnosis. Immunohistochemistry and molecular pathology for genetic profiling have been used in an attempt to resolve some of these issues. Methods Tumor tissue samples of thyroid were obtained from 70 patients who underwent surgical therapy. They were divided into 4 groups: 20 adenomatous goiters, 10 follicular adenomas, 24 papillary carcinomas, and 16 follicular carcinomas. Immunohistochemical analysis was carried out using antibodies for MAGE-A4 (melanoma antigen-encoding gene A4) and MAGE-C1 (melanoma antigen-encoding gene C1). Results Standard histologic analysis and immunohistochemistry analysis of MAGE-A4 and MAGE-C1 expression were performed in all patients. The antigens examined were not expressed in any of the tissues. Conclusions The malignant degeneration of normal tissues is a multifactorial process, varying considerably both among tumor types and among individual patients. The present study showed that there was no immunolabeling of the MAGE-A4 and MAGE-C1 antigens. © 2011 Wiley Periodicals, Inc. Head Neck, 2011 [ABSTRACT FROM AUTHOR]

Published
2011
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results